Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Sedik, S; Boyer, J; Egger, M; Dichtl, K; Prattes, J; Prüller, F; Hoenigl, M.
Comparative Analysis of the Clarus Aspergillus Galactomannan Enzyme Immunoassay Prototype for the Diagnosis of Invasive Pulmonary Aspergillosis in Bronchoalveolar Lavage Fluid.
Mycopathologia. 2024; 189(4):67
Doi: 10.1007/s11046-024-00876-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Boyer Johannes
-
Hönigl Martin
-
Prattes Jürgen
-
Sedik Sarah
- Co-Autor*innen der Med Uni Graz
-
Dichtl Karl
-
Egger Matthias Florian
-
Prüller Florian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Galactomannan (GM) testing using Platelia Aspergillus enzyme immunoassay (Platelia AGM) from bronchoalveolar lavage fluid (BALF) aids in early diagnosis of invasive pulmonary aspergillosis (IPA). Globally, only a minority of laboratories have the capability to perform on-site GM testing, necessitating accessible and affordable alternatives. Hence, we conducted a comparative evaluation of the new clarus Aspergillus GM enzyme immunoassay prototype (clarus AGM prototype) with Platelia AGM using BALF samples. METHODS: This is a single-center, prospective, cross-sectional study, where Platelia AGM testing was routinely performed followed by clarus AGM prototype testing in those with true positive or true negative AGM test results according to the 2020 EORTC/MSG and the 2024 FUNDICU consensus definitions. Descriptive statistics, ROC curve analysis, and Spearman's correlation analysis were used to evaluate analytical performance of the clarus AGM prototype assay. RESULTS: This study enrolled 259 adult patients, of which 53 (20%) were classified as probable IPA, while 206 did not fulfill IPA-criteria. Spearman's correlation analysis revealed a strong correlation between the two assays (rho = 0.727, p < 0.001). The clarus AGM prototype had a sensitivity of 96% (51/53) and a specificity of 74% (153/206) for differentiating probable versus no IPA when using the manufacturer recommended cut-off. ROC curve analysis showed an AUC of 0.936 (95% CI 0.901-0.971) for the clarus AGM prototype, while the Platelia AGM yielded an AUC of 0.918 (95% CI 0.876-0.959). CONCLUSIONS: Clarus AGM prototype demonstrated a strong correlation and promising test performance, comparable to Platelia AGM, rendering it a viable alternative in patients at risk of IPA.
- Find related publications in this database (using NLM MeSH Indexing)
-
Humans - administration & dosage
-
Mannans - analysis
-
Galactose - analogs & derivatives
-
Bronchoalveolar Lavage Fluid - microbiology, chemistry
-
Prospective Studies - administration & dosage
-
Invasive Pulmonary Aspergillosis - diagnosis
-
Immunoenzyme Techniques - methods
-
Cross-Sectional Studies - administration & dosage
-
Middle Aged - administration & dosage
-
Male - administration & dosage
-
Female - administration & dosage
-
Aspergillus - isolation & purification
-
Adult - administration & dosage
-
Sensitivity and Specificity - administration & dosage
-
Aged - administration & dosage
-
ROC Curve - administration & dosage
-
Young Adult - administration & dosage
- Find related publications in this database (Keywords)
-
Invasive pulmonary aspergillosis
-
Galactomannan
-
BALF
-
Enzyme-linked immunoassay
-
Diagnostics